

CORRECTION

Open Access



Correction: Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry

Marta Valero^{1*}, Carlos Sanchez-Piedra², Mercedes Freire³, Maria Colazo⁴, Noemi Busquets⁵, Erardo Merino-Ibarra⁶, Carlos Rodriguez-Lozano⁷, Sara Manrique⁸, Cristina Campos⁹, Fernando Sanchez-Alonso¹⁰ and Isabel Castrejon¹¹

Correction: Arthritis Res Ther 25, 86 (2023)
<https://doi.org/10.1186/s13075-023-03045-3>

Following publication of the original article [1], the authors reported an error found in the abstract section wherein the word “shorter” should be replaced by “longer”. The correct sentence should read:

The factors associated with a higher probability of discontinuation on remission were shorter disease duration (OR: 0.95; 95% CI: 0.91–0.99), no concomitant use of classic DMARDs (OR: 0.56; 95% CI: 0.34–0.92), and **longer** usage of the previous bDMARD (before the decision to discontinue biological therapy)

(OR: 1.01; 95% CI: 1.01–1.02); in contrast, smoking status (OR: 2.48; 95% CI: 1.21–5.08) was associated with a lower probability.

The original article [1] has been updated.

Published online: 25 October 2023

Reference

1. Valero M, Sánchez-Piedra C, Freire M, et al. Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry. *Arthritis Res Ther.* 2023;25:86. <https://doi.org/10.1186/s13075-023-03045-3>.

The original article can be found online at <https://doi.org/10.1186/s13075-023-03045-3>.

*Correspondence:

Marta Valero
martavaleroex@yahoo.es

¹ Servicio de Reumatología, Hospital Universitario Ramon Y Cajal Instituto Ramon Y Cajal de Investigación Sanitaria (IRYCIS), Carretera de Colmenar Viejo Km: 9,100, 28034 Madrid, Spain

² Health Technology Assessment Agency of Carlos III Institute of Health (ISCIII), Madrid, Spain

³ Department of Rheumatology, Complejo Hospitalario Universitario A Coruna, A Coruna, Spain

⁴ Department of Rheumatology, Hospital Universitario de Burgos, Burgos, Spain

⁵ Department of Rheumatology, Hospital General de Granollers, Granollers, Barcelona, Spain

⁶ Department of Rheumatology, Hospital Universitario Miguel Servet, Saragossa, Spain

⁷ Department of Rheumatology, Hospital Universitario de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain

⁸ Department of Rheumatology, Hospital Universitario Regional de Malaga (Hospital Carlos Haya), Malaga, Spain

⁹ Department of Rheumatology, Hospital General Universitario de Valencia, Valencia, Spain

¹⁰ Research Unit of Spanish Society of Rheumatology, Madrid, Spain

¹¹ Department of Rheumatology, Hospital General Universitario Gregorio Marañón Instituto de Investigación Sanitaria Gregorio Marañón (IISGM), Universidad Complutense de Madrid, Madrid, Spain



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.